Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifabutin

FDA-approved product (capsule, oral), marketed as Mycobutin, Rifabutin.

Registered studies
50+
Lab records
15
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifabutin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Mycobacterium avium complex disease
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB04; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifabutin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA84.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli64.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 15 of 15 lab records
Open Rifabutin in ChEMBL Registered studies below
Show the 15 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifabutin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

    NCT07326540 · start 2026-03-27

    Registered record
    Registry ID
    NCT07326540
    Conditions
    Hospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP); Colistin Resistanrt ABC; Acinetobacter Baumannii-calcoaceticus Complex
    Interventions
    BV100 (300 mg); Polymyxin B; Colistin; Ampicillin-Sulbactam; MEROPENEM 2 grams TID
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-27
    Completion
    2028-03-30
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP); Colistin Resistanrt ABC; Acinetobacter Baumannii-calcoaceticus Complex
    InterventionBV100 (300 mg); Polymyxin B; Colistin; Ampicillin-Sulbactam +1 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

    NCT07199452 · start 2025-10-28

    Registered record
    Registry ID
    NCT07199452
    Conditions
    Healthy
    Interventions
    MK-4646; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-10-28
    Completion
    2026-01-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMK-4646; Rifabutin
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

    NCT07066722 · start 2025-07-07

    Registered record
    Registry ID
    NCT07066722
    Conditions
    HIV Infections
    Interventions
    VH4524184; Itraconazole; Rifabutin; Phenytoin; Metformin; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-07-07
    Completion
    2025-12-17
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVH4524184; Itraconazole; Rifabutin; Phenytoin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

    NCT06731023 · start 2025-01-01

    Registered record
    Registry ID
    NCT06731023
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    Bismuth; Vonoprazan; Amoxicillin; Rifabutin; Metronidazole; Other antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    InterventionBismuth; Vonoprazan; Amoxicillin; Rifabutin +2 more
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Short-course Regimens for the Treatment of Pulmonary Tuberculosis

    NCT05766267 · start 2023-11-21

    Registered record
    Registry ID
    NCT05766267
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis Infection
    Interventions
    Rifabutin; Delamanid; Bedaquiline; Moxifloxacin; Pyrazinamide; Isoniazid; Rifampin; Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-11-21
    Completion
    2027-12-31
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis Infection
    InterventionRifabutin; Delamanid; Bedaquiline; Moxifloxacin +4 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

    NCT05685615 · start 2023-04-20

    Registered record
    Registry ID
    NCT05685615
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    BV100 plus Polymyxin B; BAT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-04-20
    Completion
    2024-12-11
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionBV100 plus Polymyxin B; BAT
    PhasePhase 2
    Registry statusCompleted

  • To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100

    NCT05684718 · start 2023-02-01

    Registered record
    Registry ID
    NCT05684718
    Conditions
    Bacterial Infections
    Interventions
    BV100 (300 mg); Itraconazole 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-02-01
    Completion
    2023-10-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionBV100 (300 mg); Itraconazole 200 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

    NCT05537142 · start 2022-09-02

    Registered record
    Registry ID
    NCT05537142
    Conditions
    Healthy Participants
    Interventions
    BV100
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-09-02
    Completion
    2024-10-30
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBV100
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants

    NCT05537090 · start 2022-09-01

    Registered record
    Registry ID
    NCT05537090
    Conditions
    Healthy Volunteers
    Interventions
    BV100; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2023-09-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBV100; Midazolam
    PhasePhase 1
    Registry statusCompleted

  • 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection

    NCT06687499 · start 2022-08-22

    Registered record
    Registry ID
    NCT06687499
    Conditions
    Helicobacter Pylori; Drug Resistance, Multiple
    Interventions
    Bismuth-based susceptibility-guided treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-22
    Completion
    2024-01-26
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori; Drug Resistance, Multiple
    InterventionBismuth-based susceptibility-guided treatment
    PhasePhase 4
    Registry statusCompleted

  • Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

    NCT04672525 · start 2021-11-08

    Registered record
    Registry ID
    NCT04672525
    Conditions
    Prosthetic Infection
    Interventions
    Rifabutin; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-11-08
    Completion
    2027-06
    Enrolment
    436

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Infection
    InterventionRifabutin; Rifampicin
    PhasePhase 3
    Registry statusRecruiting

  • Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

    NCT05086107 · start 2021-10-08

    Registered record
    Registry ID
    NCT05086107
    Conditions
    Renal Impairment
    Interventions
    BV100
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-08
    Completion
    2023-01-16
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionBV100
    PhasePhase 1
    Registry statusCompleted

  • Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

    NCT05087069 · start 2021-10-08

    Registered record
    Registry ID
    NCT05087069
    Conditions
    Healthy Volunteers
    Interventions
    BV100; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-08
    Completion
    2023-01-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBV100; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

    NCT04879992 · start 2021-05-07

    Registered record
    Registry ID
    NCT04879992
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Esomeprazole; Bismuth Potassium Citrate; Tetracycline,Metronidazole; amoxicillin rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-05-07
    Completion
    2022-10-30
    Enrolment
    413

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEsomeprazole; Bismuth Potassium Citrate; Tetracycline,Metronidazole; amoxicillin rifabutin
    PhaseNot applicable
    Registry statusCompleted